INMD Stock Price & Analysis

Inmode Ltd

INMD

Inmode Ltd

18.350

+18.350(+0%)6M

INMD Stock Price Chart

YTD

INMD Key Stats

High

18.690

Vol

1.14M

Low

18.120

Amount

21.03M

Open

18.120

VWAP

18.45

Mkt Cap

1.28B

EV/EBITDA(TTM)

5.98

INMD Company Profile

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

INMD Technical Analysis

Instant technical analysis with one click on any asset

INMD Why It Moves

Find out the reasons behind the current stock movement

Should I Buy INMD

AI-powered analysis to guide your buy, sell, or hold decision for this stock

INMD News Sentiment

AI uncovers potential trading opportunities based on news sentiment

INMD Technical Analysis

Instant technical analysis with one click on any asset

INMD Why It Moves

Find out the reasons behind the current stock movement

Should I Buy INMD

AI-powered analysis to guide your buy, sell, or hold decision for this stock

INMD News Sentiment

AI uncovers potential trading opportunities based on news sentiment

INMD Fundamental Analysis

buy

Moderate Buy

Buy

Hold

Sell

High

29.00

Averages

21.75

Low

16.00

Analyst

Rating

Action

Price Target

Date

Rating Reason

Barclays

Matt Miksic

Buy

Maintains

$26 → $29

2025-02-05

Needham

Mike Matson

Hold

Maintains

n/a

2025-02-04

Barclays

Matt Miksic

Buy

Maintains

$27 → $26

2025-01-09

Barclays

Needham

Mike Matson

Hold

Reiterates

n/a

2024-10-31

BTIG

Sam Eiber

Strong Buy

Initiates

$25

2024-10-17

Analyst	Rating	Action	Price Target	Date	Rating Reason

Barclays Matt Miksic	Buy	Maintains	$26 → $29	2025-02-05
Needham Mike Matson	Hold	Maintains	n/a	2025-02-04
Barclays Matt Miksic	Buy	Maintains	$27 → $26	2025-01-09	Barclays
Needham Mike Matson	Hold	Reiterates	n/a	2024-10-31
BTIG Sam Eiber	Strong Buy	Initiates	$25	2024-10-17

INMD Earnings Analysis

Inmode Ltd Corporation (INMD.O) Q4 2024 Earnings Conference Call

Positive

Q4 Revenue and Gross Margin: InMode generated $97,900,000 in total revenue for Q4 2024, achieving a gross margin of 79%, and for the full year, revenue totaled $394,800,000 with non-GAAP gross margins remaining the highest in the industry at 81%.
Shareholder Return Strategy: In 2024, InMode returned over $285,000,000 to shareholders through share repurchases, representing approximately 19% of its share capital, and announced a new tax-efficient share repurchase program of up to 10% of its share capital.
New Platform Launch Success: The company launched two new platforms in 2024, IgniteRF and Optimus Max, which received positive early feedback from doctors worldwide, indicating strong potential for future revenue growth.
Consumables and Services Growth: For the full year of 2024, consumables and services accounted for 20% of revenue, an increase from 16% in 2023, demonstrating growth in this segment despite overall revenue challenges.
Strong Financial Position: InMode ended 2024 with a strong balance sheet, holding cash and cash equivalents of $596,500,000, and generated $32,400,000 from operating activities in Q4, reflecting robust operational efficiency.

Negative

Revenue Decline 2024: Revenue for full year 2024 totaled $394,800,000, a decrease of 20% compared to 2023.
International Sales Decline: International sales in Q4 decreased by 23% year-over-year, totaling $35,200,000, reflecting a decline across all regions.
Operating Margin Decline: GAAP operating margin for Q4 was 28%, down from 45% in Q4 of 2023, indicating a significant drop in profitability.
Earnings Per Share Decline: Non-GAAP diluted earnings per share for 2024 were $1.76, down from $2.57 in 2023, reflecting a decline in earnings performance.
Sales and Marketing Expenses Decline: Sales and marketing expenses for the full year 2024 totaled $181,400,000, down from $193,000,000 in 2023, primarily due to lower sales commissions resulting from a decline in sales.

Positive

Q4 Revenue and Gross Margin: InMode generated $97,900,000 in total revenue for Q4 2024, achieving a gross margin of 79%, and for the full year, revenue totaled $394,800,000 with non-GAAP gross margins remaining the highest in the industry at 81%.
Shareholder Return Strategy: In 2024, InMode returned over $285,000,000 to shareholders through share repurchases, representing approximately 19% of its share capital, and announced a new tax-efficient share repurchase program of up to 10% of its share capital.
New Platform Launch Success: The company launched two new platforms in 2024, IgniteRF and Optimus Max, which received positive early feedback from doctors worldwide, indicating strong potential for future revenue growth.
Consumables and Services Growth: For the full year of 2024, consumables and services accounted for 20% of revenue, an increase from 16% in 2023, demonstrating growth in this segment despite overall revenue challenges.
Strong Financial Position: InMode ended 2024 with a strong balance sheet, holding cash and cash equivalents of $596,500,000, and generated $32,400,000 from operating activities in Q4, reflecting robust operational efficiency.

Negative

Revenue Decline 2024: Revenue for full year 2024 totaled $394,800,000, a decrease of 20% compared to 2023.
International Sales Decline: International sales in Q4 decreased by 23% year-over-year, totaling $35,200,000, reflecting a decline across all regions.
Operating Margin Decline: GAAP operating margin for Q4 was 28%, down from 45% in Q4 of 2023, indicating a significant drop in profitability.
Earnings Per Share Decline: Non-GAAP diluted earnings per share for 2024 were $1.76, down from $2.57 in 2023, reflecting a decline in earnings performance.
Sales and Marketing Expenses Decline: Sales and marketing expenses for the full year 2024 totaled $181,400,000, down from $193,000,000 in 2023, primarily due to lower sales commissions resulting from a decline in sales.